AbstrAct
IntroductIon
Age is a major risk factor for the development of cardiovascular diseases (CVD), independently from traditional risk factors. 1 An important factor that contributes to organismal aging, including vascular aging, is genomic instability. 2, 3 We recently demonstrated that mutation of the DNA repair endonuclease excision repair cross complementing 1 in mice (Ercc1 d/-mice) accelerates important characteristics of vascular aging-related vasomotor dysfunction. 4, 5 In general, Ercc1 d/-mice rapidly and faithfully mimic natural human aging compared to aged wild-type (WT) mice. 6 Accordingly, mouse models of accelerated vascular aging due to genomic instability can be used as tools complementary to models representing the impact of classical risk factors, such as hypertension and dyslipidemia.
We demonstrated that dietary restriction (DR, 30% reduced food intake without malnutrition), a universal intervention extending lifespan in numerous species, tripled remaining lifespan and strongly improved health span in Ercc1 d/-animals, by far exceeding the relative lifespan extension in WT mice. We found that this dramatic anti-accelerated aging effect in the mutant was at least in part due to preserving genomic integrity by reducing DNA damage accumulation. 2 The improvement of health span included prevention of endothelial dysfunction, which in humans is one of the major contributors to morbidity and mortality due to a decline in vascular function. 1 In humans, DR has a beneficial effect on cardiovascular risk, which is attributed to the reduction in diet-related risk factors such as dyslipidemia, high blood pressure (salt intake), and hyperglycemia. 7 This in turn reduces oxidative stress and augments the nitric oxide (NO) -cGMP pathway, an important endothelial signaling axis involved in blood flow, blood pressure and cardiovascular growth regulation. 7 Our results in Ercc1 d/-mice have added a novel paradigm, namely that DR preserves genomic integrity and thus in this manner protects against vascular aging.
In this new paradigm it is not known which vasodilatory signaling pathway is improved. In our previous studies we have shown that, comparable to human aging, Ercc1 d/-mice display a reduction of NO -cGMP signaling and increased oxidative stress. 4, 5 Therefore, we here set out to identify which vasodilatory signaling pathway is improved by DR in Ercc1 d/-mice. In addition, the impact of DR on endothelium-independent relaxation was investigated.
A potential mediator of blood pressure increase and decreased endotheliumdependent relaxation caused by DNA damage is activation of the renin-angiotensin system (RAS). Angiotensin (Ang) II, the main bioactive hormone of this system, is strongly involved in hypertension, arteriosclerosis, vascular DNA damage and cell senescence, inflammation, oxidative stress, longevity and health span. 8 Also, Ang II inhibits eNOS -NO -cGMP signaling. 9 Given that the RAS is sensitive to salt and LDL cholesterol, it may also respond to DR. 10 
MAterIAl And Methods

Animals and interventions
Animal experiments were performed at RIVM and Erasmus MC in accordance with the Principles of Laboratory Animal Care and with the guidelines approved by the Dutch Ethical Committee in full accordance with European legislation.
Dietary restriction studies
Ercc1 d/-mice and their wild-type littermates (WT) (Bl6/FVB F1 hybrids) underwent DR intervention from resp. 7 and 11 weeks after birth until sacrifice as described extensively in our previous publication, and in the Methods supplement. 
Losartan intervention study
From 5 weeks of age, Ercc1 d/-and WT mice (Bl6/FVB F1 hybrids) were divided into two groups per strain, which were either treated with losartan (100 mg/kg/day) in drinking water, or drinking water only until the age of 12 weeks when the animals were sacrificed.
Blood pressure was measured by tail cuff at the age of 11 weeks. The study rationale and animal numbers are described in the Methods supplement.
organ bath experiments
Tissue harvesting and preparation procedures, and detailed description of the organ bath experiments can be found in the Methods supplement.
In short, thoracic aorta and iliac arteries were collected and tested in small wire organ bath setups. Vasodilations to cumulative concentrations of acetylcholine (ACh) and sodium nitroprusside (SNP) were measured in vessels preconstricted with U46619
to construct concentration-response curves (CRCs). When sufficient aortic tissue was available, the involvement of nitric oxide (NO) and prostaglandins in ACh responses was investigated by performing the experiments in the presence of the endothelial nitric oxide 
Quantitative real-time Pcr
Total RNA was isolated and cDNA was prepared, which was amplified by real-time PCR to perform ΔΔCt quantification, either with the use of SYBR green or Taqman analysis.
Further details are in the Methods supplement. 1E ). The data confirmed that in AL-fed Ercc1 d/-mice SNP responses were strongly reduced, and that they were fully restored to the level of WT animals by DR. In WT animals no significant changes occurred.
Plasma renin concentration
The response to ACh depends on the amount of relaxing factors that is released from the endothelium as well as the responsiveness of the VSMC to these factors. The present observation that responses of VSMC to NO are fully restored by DR (Fig. 1C, E) while the responses to ACh are not (Fig. 1B) , suggests that the release of endothelial-derived relaxing factors is compromised. Therefore, we studied the contribution of these factors to vasodilation.
the role of endothelial signaling compounds in genotype-and diet-related effects
Dilations in AL-fed vs. DR-fed WT mice did not differ and results were therefore pooled.
ACh responses were almost completely dependent on NO in WT animals since adding the eNOS inhibitor L-NMMA blocked the response to ACh (Fig. 2A) . As expected from our previous study 4 , NO also mediated a large part of the vasodilation to ACh in AL-fed Ercc1 d/-mice (Fig. 2B) . The residual response suggests the emergence of an endothelium-derived hyperpolarizing factor (EDHF), which did not appear to be COX-dependent, since it was not affected by indomethacin (Fig. 2B ). This result, together with the observation that (Fig. 2C) . Prostaglandins are produced by COX-1 or 2, and exert their vasodilator eff ects through the IP receptor using adenylyl cyclase (AC) 5/6 -cAMP signaling as a second messenger system. cAMP is prone to degradation by phosphodiesterase type 4B/D (PDE4). [13] [14] [15] To investigate which of these components could be responsible for the upregulated prostaglandin response we quantifi ed their expression in blood vessel-rich lung tissue.
Ct values for the IP receptor, PDE4D and AC6 mRNA levels were on average >34, and therefore we considered these levels too low for reliable detection. COX-1 mRNA showed a trend to increase (p<0.05 one-way ANOVA for all 4 groups) after DR in WT and in Ercc1 d/-mice, and did signifi cantly increase in DR-fed Ercc1 d/-mice as compared with AL-fed WT mice (Fig. 3A) . PDE4B mRNA was decreased in both Ercc1 d/-mouse groups compared with AL-fed WT mice (Fig. 3A) . COX-2 and AC 5/6 mRNA did not show signifi cant changes among the groups. The results suggest that both an increase of prostaglandin production by COX1 and decreased metabolism by PDE4B underlie the improved vasodilation after 
eff ects of genomic instability and dr on Ang II responses
To explore a possible role of the renin-angiotensin system we fi rst investigated vasoconstriction to Ang II in a subset of the diet intervention mice. Ang II responses were in general highly variable within each strain, and tended to be higher in AL-fed Ercc1 d/-vs.
AL-fed WT mice (Fig. 2D) 
the losartan interventi on study
In a separate cohort of Ercc1 d/-and WT mice we evaluated the eff ect of chronic AT 1 receptor blockade on blood pressure and vascular function. In agreement with our previous study 4 blood pressure tended to be slightly higher in Ercc1 d/-mice, mainly refl ected by systolic blood pressure (SBP), and to a lesser extent by diastolic blood pressure (DBP) (Fig. 4) . The diff erence reached borderline signifi cance for SBP (p = 0.076, t-test). Chronic AT 1 receptor blockade by losartan signifi cantly lowered SBP and DBP in both mouse strains. we therefore explored other indicators of increased AT 1 receptor activity such as negative feedback on renin activity and ACE expression. Plasma renin activity was reduced (Fig. 3C ). This was not due to a change in mRNA level in the kidney (Fig. 3B) . ACE mRNA in the lung was reduced (Fig. 3B ). Both findings are in agreement with increased AT 1 receptor activity.
To further explore mechanisms leading to increased Ang II vasoconstrictions we studied vascular AT 1 and AT 2 receptor expression and function. We and others previously reported that AT 2 receptor stimulation counteracts AT 1 receptor-mediated vasoconstriction. 16 To explore the effect of genomic instability on AT 2 Since increased AT 1 receptor signaling is believed to be involved in vascular disease related to endothelial dysfunction, a role that might both provoke as wells as be mediated by increased blood pressure, we tested the effect of chronic losartan treatment on
effect of chronic losartan treatment on accelerated age-related vasodilator dysfunction
In the 12-wk-old Ercc1 d/-mutants vasodilator responses to ACh were significantly decreased as compared to WT animals (Fig. 5C ). The dilation response to a SNP concentrationresponse curve was also decreased in Ercc1 d/-mice (Fig. 5D ). Chronic AT 1 receptor blockade with losartan in vivo did not significantly change any of the responses. Our findings indicate that the observed vasodilator dysfunction (persistent after losartan) was not blood pressure-dependent and that the detrimental effect of genomic instability cannot be opposed by chronic AT 1 receptor blockade with Losartan.
dIscussIon
In the present study we explored potential mechanisms that lead to DR-mediated improvement of vasodilator dysfunction caused by DNA damage. Loss of vasodilation was entirely due to loss of NO-cGMP signaling, both as a result of decreased endothelial NO release and decreased VSMC responsiveness to NO. In previous publications we showed that the decreased NO function was due to decreased eNOS expression and activation, increased PDE1 and possibly also PDE5 activity, and for a small part due to increased ROS production. 4, 5 The present results indicate that DR improves vascular dilations up to an age of at least 30 weeks. This is because DR enables aortic tissue to recruit endothelium-derived vasodilatory prostaglandins, which are normally absent. In addition, the responsiveness of VSMC to NO is improved. A possible explanation for the emerging prostaglandin response is the increase in COX-1 combined with a decreased in PDE4B, which together should lead Preservation of endothelium-dependent responses by DR has been previously reported in aging WT rodents, involving nuclear factor erythroid-2-related factor-2 (Nrf2)- 18 , our results confirm the observation that DR prevents the decline of plasma and renal prostacyclin levels in aging rats. 19, 20 Another study shows rather diverse changes, claiming lower levels of both vasoconstrictive and vasodilatory COX products after DR in the aging rat aorta. 21 Although both findings indicate the participation of COX products in DR-induced changes, this topic has attracted little attention until now. Nevertheless, the combined improvement of VSMC responses to NO-cGMP and increased prostaglandin-cAMP by the endothelium explains the effect of DR.
Ang II responses increased in AL-fed Ercc1 d/-mice compared to WT, whereas plasma renin activity decreased. The latter result is in agreement with the observation that renin levels decrease with age. 22, 23 Although renin levels start decreasing already when approaching middle age, our present findings indicate that the aging process might contribute to this decrease. With respect to the effect of aging on AT 1 receptor-mediated vasoconstrictions many contrasting findings have been described, depending on the species or the vessels that have been used. [24] [25] [26] [27] [28] The endothelial dysfunction observed in the present study was clearly not related to Ang II and increased blood pressure. In patients, the effect of chronic AT 1 receptor blockade on preservation of vasodilator function is variable, having either a protective effect or not. 36 It was assumed that this might depend on the underlying disease or the vessel type that is investigated. However, our study suggests that the aging process might explain such variation. Unfortunately, most of the human studies exploring the effect of chronic AT1 receptor blockade focus on patients around 60 and younger, and not on the oldest old.
Nevertheless, there are clues that aging affects the effectiveness of AT 1 receptor blockade.
It has been shown that losartan becomes gradually less effective in aging rats, especially in the presence of hypertension and after loss of endothelium-independent NO function. 37 Clinical observations show that losartan/antihypertensive treatment can lead to adverse cognitive effects in elderly, which is ascribed to perfusion problems. 38 However, the same study suggests that this perfusion problem is a result of both blood pressure lowering and a persisting vascular dysfunction, at least in the brain. This implicates that vasodilator function is not improved. More dedicated studies in the oldest patients are necessary to resolve this paradox. There are mechanistic explanations available for this paradigm. In patients or in models of heart failure, hypertension, diabetes etc. Ang II blockade largely improves endothelial function due to an acute reduction of ROS formation by NAPH oxidase, increasing NO bioavailability. 9 DNA damage largely lowers NO independently from ROS 4 , and apparently this undermines the treatment efficacy of AT 1 antagonists in our mouse model. It is therefore relevant to find tools to investigate this possibility in humans. Suboptimal effectiveness of and treatment response variability to RAS inhibition are well-known phenomena, but remain largely unexplained, and therefore drive studies that attempt to find prediction markers for therapy effectiveness.
39, 40
clInIcAl PersPectIves DR is a very efficient intervention to prevent vasodilator dysfunction caused by genomic instability. In this study we set out to identify potential mechanisms that lead to DRmediated improvement of vasodilator dysfunction caused by DNA damage.
• Improvement of prostaglandin-mediated endothelium-dependent signaling and of VSMC responses to NO were identified as mechanisms. Endothelial dysfunction induced by genomic instability is not reversible with chronic losartan treatment.
• Mouse models of genomic instability appear to represent the RAS blockade-resistant part of aging-related vascular disease, and might be tools to further explore this clinically relevant issue. Further study on the effect of genomic instability might offer a novel source of mechanistic explanations and markers with potential for clinical translation. Vasodilator dysfunction in aging 15
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